JP2014528446A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528446A5
JP2014528446A5 JP2014534619A JP2014534619A JP2014528446A5 JP 2014528446 A5 JP2014528446 A5 JP 2014528446A5 JP 2014534619 A JP2014534619 A JP 2014534619A JP 2014534619 A JP2014534619 A JP 2014534619A JP 2014528446 A5 JP2014528446 A5 JP 2014528446A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
azetidin
imidazole
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014534619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/058220 external-priority patent/WO2013052395A1/en
Publication of JP2014528446A publication Critical patent/JP2014528446A/ja
Publication of JP2014528446A5 publication Critical patent/JP2014528446A5/ja
Withdrawn legal-status Critical Current

Links

JP2014534619A 2011-10-06 2012-10-01 1,3−置換アゼチジンpde10阻害剤 Withdrawn JP2014528446A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544065P 2011-10-06 2011-10-06
US61/544,065 2011-10-06
PCT/US2012/058220 WO2013052395A1 (en) 2011-10-06 2012-10-01 1,3-substituted azetidine pde10 inhibitors

Publications (2)

Publication Number Publication Date
JP2014528446A JP2014528446A (ja) 2014-10-27
JP2014528446A5 true JP2014528446A5 (enExample) 2015-11-19

Family

ID=48044097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534619A Withdrawn JP2014528446A (ja) 2011-10-06 2012-10-01 1,3−置換アゼチジンpde10阻害剤

Country Status (8)

Country Link
US (1) US9365562B2 (enExample)
EP (1) EP2763672B1 (enExample)
JP (1) JP2014528446A (enExample)
AR (1) AR088258A1 (enExample)
AU (1) AU2012318874A1 (enExample)
CA (1) CA2851082A1 (enExample)
TW (1) TW201321369A (enExample)
WO (1) WO2013052395A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2645968T3 (es) 2011-09-27 2017-12-11 Novartis Ag 3-(pirimidin-4-il)-oxazolidin-2-onas como inhibidores de IDH mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014078217A1 (en) * 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclopropyl imidazopyridine pde10 inhibitors
WO2014078216A1 (en) * 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
TW201422610A (zh) * 2012-11-15 2014-06-16 Merck Sharp & Dohme 作爲pde10抑制劑之經二級醇取代之三唑
WO2014081617A1 (en) 2012-11-20 2014-05-30 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as pde10 inhibitors
WO2014081619A1 (en) 2012-11-20 2014-05-30 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
AU2014229313B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
FR3040057A1 (fr) * 2015-08-13 2017-02-17 Inventiva Composes de type azetidine carboxylique
US10583269B2 (en) 2016-06-01 2020-03-10 Becton, Dickinson And Company Magnetized catheters, devices, uses and methods of using magnetized catheters
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
IL316875A (en) 2018-10-05 2025-01-01 Annapurna Bio Inc Compounds and compositions for treating conditions associated with APJ receptor activity
WO2021163727A1 (en) * 2020-02-11 2021-08-19 AcuraStem Incorporated Pikfyve kinase inhibitors
WO2025049402A1 (en) * 2023-08-28 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL335235A1 (en) * 1997-02-19 2000-04-10 Berlex Lab N-heterocyclic derivatives as nos inhibitors
WO2003087064A1 (en) * 2002-04-18 2003-10-23 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
PL377847A1 (pl) * 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
JP2008534481A (ja) * 2005-03-23 2008-08-28 アストラゼネカ アクチボラグ インスリン様増殖因子−1受容体活性の阻害剤としての2−アゼチジニル−4−(1h−ピラゾール−3−イルアミノ)ピリミジン
JP2008540443A (ja) * 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン
AU2007260527A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
DE102006050513A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
SI2120579T1 (sl) 2006-12-28 2014-03-31 Abbvie Inc. Inhibitorji poli (adp-riboze)polimeraze
NZ586121A (en) 2007-12-13 2012-03-30 Siena Biotech Spa Benzimidazole derivatives as hedgehog pathway antagonists and therapeutic applications thereof
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
WO2011143129A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
EP2621276B1 (en) 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
PL2748151T3 (pl) 2011-08-25 2016-09-30 Pirymidynowe inhibitory pde10

Similar Documents

Publication Publication Date Title
JP2014528446A5 (enExample)
JP2016512259A5 (enExample)
CA2592986C (en) Heteroaromatic quinoline compounds
JP2014521711A5 (enExample)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
JP2014531465A5 (enExample)
US20130018039A1 (en) Imidazolyl-imidazoles as kinase inhibitors
ME02416B (me) Trpv4 antagonisтi
AU2012318874A1 (en) 1,3-substituted azetidine PDE10 inhibitors
JP2014518214A5 (enExample)
JP2017533946A5 (enExample)
JP2018522046A5 (enExample)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
SI2763982T1 (en) Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases
EP1979343A2 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
JP2017528519A5 (enExample)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JP2017500364A5 (enExample)
HRP20200440T1 (hr) 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori
CA2899904A1 (en) Flap modulators
JP2016514717A5 (enExample)
US10894784B2 (en) Heteroarylbenzimidazole compounds
JP2016522231A5 (enExample)
JP2020529419A5 (enExample)